The estimated Net Worth of Thomas Finnerty is at least $1.75 Milion dollars as of 9 March 2022. Mr. Finnerty owns over 2,548 units of Anika Therapeutics stock worth over $614,641 and over the last 7 years he sold ANIK stock worth over $0. In addition, he makes $1,135,880 as Executive Vice President of Human Resources at Anika Therapeutics.
Sign up
Mr. Finnerty ANIK stock SEC Form 4 insiders trading
Thomas has made over 3 trades of the Anika Therapeutics stock since 2021, according to the Form 4 filled with the SEC. Most recently he exercised 2,548 units of ANIK stock worth $61,789 on 9 March 2022.
The largest trade he's ever made was exercising 5,834 units of Anika Therapeutics stock on 25 February 2022 worth over $141,475. On average, Thomas trades about 1,292 units every 34 days since 2017. As of 9 March 2022 he still owns at least 25,346 units of Anika Therapeutics stock.
You can see the complete history of Mr. Finnerty stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Thomas Finnerty biography
Thomas Finnerty serves as Executive Vice President of Human Resources of the Company. Mr. Finnerty served as a human resources consultant to our company. Prior to his work with Anika, Mr. Finnerty served as the Senior Vice President of Human Resources at Smith & Nephew, a leading portfolio medical technology company manufacturing products for global distribution, from 1999 through April 2016 where he was responsible for delivering value-added programs, processes and leadership in global human capital management. Mr. Finnerty has also held human resources positions at Novartis/Chiron Diagnostics and the Foxboro Company. Mr. Finnerty holds B.S. in business from the University of Massachusetts Dartmouth and an M.B.A. from Babson College.
What is the salary of Thomas Finnerty?
As the Executive Vice President of Human Resources of Anika Therapeutics, the total compensation of Thomas Finnerty at Anika Therapeutics is $1,135,880. There are 1 executives at Anika Therapeutics getting paid more, with James Loerop having the highest compensation of $1,479,630.
How old is Thomas Finnerty?
Thomas Finnerty is 62, he's been the Executive Vice President of Human Resources of Anika Therapeutics since 2019. There are 5 older and 12 younger executives at Anika Therapeutics. The oldest executive at Anika Therapeutics Inc. is Joseph Bower, 81, who is the Independent Chairman of the Board.
Insiders trading at Anika Therapeutics
Over the last 21 years, insiders at Anika Therapeutics have traded over $58,649,775 worth of Anika Therapeutics stock and bought 34,227 units worth $758,329 . The most active insiders traders include Charles H Sherwood, Farmaceutici S.P.A. Fidia oraz Joseph H Capper. On average, Anika Therapeutics executives and independent directors trade stock every 47 days with the average trade being worth of $613,258. The most recent stock trade was executed by Cheryl R Blanchard on 11 March 2024, trading 64,480 units of ANIK stock currently worth $1,563,640.
What does Anika Therapeutics do?
who we are we are anika therapeutics, a global medical technology company at the forefront of pain management, tissue regeneration and wound healing. we are committed to delivering innovative medical solutions that help patients feel better faster, look and feel younger and remain active. with over 7 million procedures performed over the past twenty years utilizing our proprietary technology, anika is helping individuals all over the world return to life naturally. our guiding principles we are innovators and creators. we value strong discipline and exceptional focus from our personnel, and we employ lean principles and agile processes in managing our business. this foundation of guiding values, combined with our entrepreneurial spirit, gives anika the ability and fortitude to generate innovative ideas and to grow our portfolio of successful products. what we do anika offers a broad spectrum of therapeutic treatments ranging from pain management and tissue regeneration to wound care an
What does Anika Therapeutics's logo look like?
Complete history of Mr. Finnerty stock trades at Anika Therapeutics
Anika Therapeutics executives and stock owners
Anika Therapeutics executives and other stock owners filed with the SEC include:
-
James Loerop,
Executive Vice President - Business Development and Strategic Planning -
Thomas Finnerty,
Executive Vice President of Human Resources -
Dr. Cheryl Renee Blanchard Ph.D.,
Pres, CEO & Director -
David Colleran,
Exec. VP, Gen. Counsel & Corp. Sec. -
James Loerop,
Exec. VP of Bus. Devel. & Strategic Planning -
Michael L. Levitz,
Exec. VP, CFO & Treasurer -
Thomas M. Finnerty,
Exec. VP of HR -
Joseph Bower,
Independent Chairman of the Board -
Jeffery Thompson,
Independent Director -
Raymond Land,
Independent Director -
Glenn Larsen,
Independent Director -
Cheryl Blanchard,
President, Chief Executive Officer, Director -
Susan Vogt,
Independent Director -
Dr. Cheryl R. Blanchard,
Pres, CEO & Director -
Stephen Richard,
Independent Director -
John Henneman,
Independent Director -
David Colleran,
Executive Vice President, General Counsel, Secretary -
Michael Levitz,
Chief Financial Officer, Executive Vice President, Treasurer -
Anne Nunes,
VP of Operations -
Bart Bracy,
VP of Sales & Marketing of Americas -
James Chase,
Sr. VP of International Sales & Marketing -
Charles Sherwood III,
VP & Corp. Legal Counsel -
Mark Namaroff,
Exec. Director of Investor Relations & Corp. Communications -
Alexei Goraltchouk,
Sr. VP of Operations & Project Management -
Richard Hague,
Chief Commercial Officer -
Edward S. Ahn,
Chief Tech. & Strategy Officer -
Charles H Sherwood,
President and CEO -
Sylvia Cheung,
Chief Financial Officer -
Steve E Wheeler,
Director -
Dana M. Alexander,
Chief Operations Officer -
Stephen R. Mascioli,
Chief Medical Officer -
John C Moran,
Director -
Joseph G Darling,
President and CEO; Director -
Gary P Fischetti,
Director -
Sheryl L Conley,
Director -
John W Jr Sheets,
Chief Scientific Officer -
Farmaceutici S.P.A. Fidia,
10% owner -
Peter Litman,
VP, Business Development -
William J Knight,
Chief Financial Officer -
Harvey S Sadow,
Director -
William Mrachek,
V.P., Human Resources -
Samuel F Mckay,
Director -
Eugene A Davidson,
Director -
Francesco J Luppino,
Chief Operating Officer -
Carol A Barnett,
Chief Commercial Officer -
Kevin W Quinlan,
Chief Financial Officer -
Constance H Garrison,
VP Reg.,Clinical & Qlty. Sys. -
James E O Neill,
Chief Accounting Officer -
Carol A Toth,
Vice President, R & D -
Elizabeth Chen,
Sr. VP Mktg. & Bus. Dev. -
Anne Nunes,
SVP, Chief Operations Officer -
Stephen D. Griffin,
EVP, CFO and Treasurer -
Joseph H Capper,
Director -
William R Jellison,
Director